Navigation Links
Par Pharmaceutical to Host Third Quarter 2008 Results Conference Call on November 7 at 9:00 am
Date:10/28/2008

WOODCLIFF LAKE, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it will host a conference call and live webcast on Friday, November 7, 2008 at 9:00 am EST to review results for the third quarter ended September 27, 2008. The Company will release results after the market closes on Thursday, November 6, 2008. The earnings release will be available on the Par website at http://www.parpharm.com.

Access to the live webcast can be made via the Company's website at http://www.parpharm.com. The dial-in numbers for the conference call will be 888-713-4214 for domestic callers and 617-213-4866 for international callers. The passcode is 32232063. A replay of the conference call will be available for two weeks approximately one hour after the call. The dial-in numbers for the replay are 888-286-8010 for domestic callers and 617-801-6888 for international callers. When prompted, the passcode is 59063488.

About Par

Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit http://www.parpharm.com.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
2. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
3. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
4. Anadys Pharmaceuticals to Present at Bio Investor Forum
5. InfaCare Pharmaceutical Corporation Raises $28 Million in Series B Financing to Advance Its Neonatal Pipeline
6. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Global Pharmaceutical Contract Manufacturing Market to Reach Over $31 Billion by 2012 According to a New Report by Global Industry Analysts, Inc.
9. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
10. Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders
11. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... vaccine that wards off infections , , THURSDAY, March 6 ... found on streptococcus bacteria may provide protection against strep ... by University of California, San Diego (UCSD), researchers developed ... streptococcal M protein, which plays a critical role in ...
... N.J., March 6 Smart Balance Inc. (Nasdaq:,SMBL) ... http://www.smartbalance.com on,March 14, 2008, at 9:30 a.m. ... will be issued at approximately 7 a.m. EDT ... mode. The webcast is also,available through the following ...
... those ... services - Immediate Termination of Endoscopy Center of Nevada clinics ... - Online information Available to Public, LAS VEGAS, March 6 Anthem ... Blue Shield,Foundation will make a $50,000 grant to the Nevada Health Centers to go,toward ...
... Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ), today announced that it ... ended Dec. 31, 2007, after the,close of market on March ... 13, 2008, at 2 p.m. PDT (5 p.m. EDT)., ... EDT, March,13, 2008, Participants are invited to call 877-545-1491 ...
... Calif., March 6 Longs Drug,Stores Corporation (NYSE: LDG ) today reported preliminary total retail drug,store sales ... in the comparable period,a year ago., , (Dollars in millions) ... retail drug store sales ... ...
... Inc. (Nasdaq: IDIX ), a biopharmaceutical company ... the treatment of human viral,and other infectious diseases, ... and year ended December 31, 2007. At December ... totaled,$112.0 million., Significant company ...
Cached Medicine News:Health News:Scientists Engineer Protein That Could Battle Strep 2Health News:Smart Balance to Host Webcast/Conference Call on 2007 Fourth-Quarter and Full-Year Results 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 3Health News:Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call 2Health News:Longs Reports Preliminary February Retail Drug Store Sales 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs announces ... in Albany, NY for admixing, ... company meets and/or exceeds the FDA standards for safety ... CFR Part 211. The 10,000 square ... levels of quality assurance and quality control. The company ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5